Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

RGENIX to Present at Multiple Virtual Healthcare Investor Conferences in August

New York, NY  Aug 052020 – RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that it has been selected to present at multiple virtual healthcare investor conferences taking place during the month of August.  

These conferences include:  

August 5, 2020 at 11:30 A.M EDT  

August 11, 2020 at 3:30 P.M. EDT  

August 12, 2020 at 9:10 A.M. EDT  

August 13, 2020 at 8:00 A.M. EDT  

Links to the live and archived versions of these presentations are available on Rgenix’s website within the News section.  

About RGENIX 

RGENIX, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancer progression. The company is pursuing several first-in-class drug candidates to treat cancers of high unmet need. RGENIX identifies novel cancer targets using a microRNA based target discovery platform originally developed by RGENIX’s scientific co-founders at The Rockefeller University and now exclusively licensed to RGENIX. The company brings together distinguished scientific founders, a seasoned Board, and a leadership team comprised of experienced drug developers. The company is funded by leading biotechnology investors, including Novo Holdings A/S, Sofinnova Partners, Lepu Holdings Limited, Oceanpine Capital, WuXi PharmaTech Healthcare Fund I, LP, Alexandria Venture Investments, LLC, Exor Seeds, and the Partnership Fund for New York City. For more information, please visit www.rgenix.com. 

Media Contact:

RooneyPartners
Jeanene Timberlake
646-770-8858
jtimberlake@rooneyco.com